Dr. Albert S. Denittis, MD

Dr. Denittis practices at East Norriton Ambulatory Surgery in East Norriton, Pennsylvania.

Dr. Denittis' NPI, 1134129349, was assigned on July 29, 2005. Dr. Denittis holds Pennsylvania license MD063741L.

Dr. Denittis' primary practice is East Norriton Ambulatory Surgery, at 325 West Germantown Pike Suite 100, East Norriton, PA 19403. The practice phone is (610) 272-1881.

Dr. Denittis' primary practice is East Norriton Ambulatory Surgery in East Norriton, Pennsylvania. Dr. Denittis is also affiliated with Lankenau Medical Center. The medical group on file is MidLantic Urology. Dmand AI also links Dr. Denittis to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Denittis practices, 4 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Denittis' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Denittis is licensed in Pennsylvania.

CMS data shows 4,603 Medicare services from Dr. Denittis across 11 procedure codes in 2024, for 130 Medicare patients. Medicare paid $861,239 for them. Every service was in an office.

CMS counts 130 Medicare patients who saw Dr. Denittis in 2024. The largest group is 65 to 74, with 62 patients. 75% of them have cancer, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.38, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Denittis' median patient age at 72, with 3% women.

In 2024, Dr. Denittis wrote 94 Medicare Part D claims for 48 patients. 99% of them were for generic drugs. CMS names the drug for 72 of them, across 1 drug with 11 or more claims each, at $697 in total drug cost. In 2023, CMS named 102 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Denittis for performance year 2024, reported as part of a group. Dr. Denittis accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 23 papers to Dr. Denittis, published from 2010 to 2021. 2016 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Algorithms. Dr. Denittis has published most often in Int J Radiat Oncol Biol Phys. Dr. Denittis' most frequent co-authors are Vinai Gondi, MD, Lisa Ann Kachnic, MD and Mitchell Machtay, MD.

Dmand AI links Dr. Denittis to 10 clinical trials, 6 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Breast Neoplasms and Lung Neoplasms. National Cancer Institute (NCI) sponsors the most, 7.

CMS Open Payments shows 237 general payments to Dr. Denittis from 48 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Janssen Pharmaceuticals, Inc paid the most, $961.